

A2  
63. A transdermal drug delivery system according to claim 44, wherein the physiologically active agent or prodrug thereof, the dermal penetration enhancer, and the volatile liquid are a single phase.


64. A method according to claim 57, wherein the drug delivery system is applied by an aerosol or spray comprising a shroud adapted to keep an actuator nozzle of the apparatus at a pre-determined height above the site of application.

**REMARKS**

This application is a divisional of U.S. Application Serial No. 09/125,436, filed December 18, 1998. Entry of the above amendments is respectfully requested. New claims 39-64 substantially correspond to originally filed claims 1, 3-5, 10, 12, 15, 16-31 and 39-41, respectively. No new matter has been entered.

If the Examiner has any questions regarding this submission, he is invited to contact the undersigned attorney at the telephone number set forth below.

Respectfully submitted,

  
Stephen A. Bent  
Registration No. 29,768

July 24, 2001  
Date

FOLEY & LARDNER  
Suite 500, 3000 K Street, N.W.  
Washington, D.C. 20007-5109  
(202) 672-5300  
(202) 672-5599

Should additional fees be necessary in connection with the filing of this paper, the Commissioner is hereby authorized to charge Deposit Account No. 19-0741 for any such fees.